

12th September, 2026

To, The General Manager Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701 (Equity) : 975834, 976560, 977467, 977859 and 978062 (Debt)	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB.: Disclosure pursuant to Regulations 30 and 51 of SEBI (LODR) Regulations, 2015: The Company’s wholly owned subsidiary, CARBOGEN AMCIS AG successfully completed US FDA Inspection at its manufacturing site located at Vionnaz, Switzerland without any observations.

Dear Sir,

With reference to the captioned subject, we would like to inform that yesterday the Company’s wholly owned subsidiary, CARBOGEN AMCIS AG’s manufacturing site located at Vionnaz, Switzerland, has successfully completed its first U.S. Food and Drug Administration (FDA) inspection without any Form 483.

This successful inspection reflects the strong focus on quality parameters across the Company and its subsidiaries. The Company’s sites worldwide remain approved by major regulatory agencies.

Kindly take this on your record & oblige.

Thanking you.

Yours faithfully,
For, Dishman Carbogen Amcis Limited**Shrima Dave**
Company Secretary